CIA
NBIX icon

CSat Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History

CSat Investment Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,622
Closed -$156K – 797
2020
Q3 		$156K Sell
1,622
-624
-28% -$72.2K 0.01% 326
2020
Q2 		$274K Buy
2,246
+1,420
+172% +$157K 0.03% 257
2020
Q1 		$71K Sell
826
-148
-15% -$14.5K 0.02% 436
2019
Q4 		$105K Sell
974
-850
-47% -$89K 0.03% 348
2019
Q3 		$164K Buy
1,824
+328
+22% +$30.6K 0.05% 239
2019
Q2 		$126K Buy
+1,496
New +$123K 0.04% 259

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CSat Investment Advisory's NBIX Position: Q4 2020 in Review

CSat Investment Advisory sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 1,622 shares — an estimated $156K sold.

CSat Investment Advisory first reported a position in NBIX in Q2 2019 and held it in 6 quarters. The position peaked at $274K in Q2 2020. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • CSat Investment Advisory reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 1,622 Neurocrine Biosciences shares in Q4 2020, an estimated $156K.
  • CSat Investment Advisory first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 6 quarters.
  • CSat Investment Advisory's Neurocrine Biosciences position peaked at $274K in Q2 2020.
  • 406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.